HCV core protein inhibits polarization and activity of both M1 and M2 macrophages through the TLR2 signaling pathway

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Zhang, Qianqian ^a,b   Wang, Yang ^a   Zhai, Naicui ^a   Song, Hongxiao ^a   Li, Haijun ^a   Yang, Yang ^a   Li, Tianyang ^a   Guo, Xiaolin ^a   Chi, Baorong ^a   Niu, Junqi ^a   Crispe, Ian Nicholas ^a,c   Su, Lishan ^a,d   Tu, Zhengkun ^a  

^a THE FIRST HOSPITAL OF JILIN UNIVERSITY   (China)

^b JINING MEDICAL UNIVERSITY   (China)

^c UNIVERSITY OF WASHINGTON   (United States)

^d UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; CORE PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; NUCLEOCAPSID PROTEIN, HEPATITIS C VIRUS; TOLL LIKE RECEPTOR 2; TUMOR NECROSIS FACTOR;

ADULT; ANTAGONISTS AND INHIBITORS; CASE CONTROL STUDY; CD4+ T LYMPHOCYTE; CELL CULTURE; CELL DIFFERENTIATION; CYTOLOGY; FEMALE; GENETICS; HEPACIVIRUS; HEPATITIS C; HUMAN; ISOLATION AND PURIFICATION; MACROPHAGE; MALE; METABOLISM; MIDDLE AGED; MONOCYTE; PATHOLOGY; SIGNAL TRANSDUCTION; VIROLOGY;

ADULT; ANTIVIRAL AGENTS; CASE-CONTROL STUDIES; CD4-POSITIVE T-LYMPHOCYTES; CELL DIFFERENTIATION; CELLS, CULTURED; FEMALE; HEPACIVIRUS; HEPATITIS C; HUMANS; MACROPHAGES; MALE; MIDDLE AGED; MONOCYTES; NITRIC OXIDE SYNTHASE TYPE II; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTOR 2; TUMOR NECROSIS FACTOR-ALPHA; VIRAL CORE PROTEINS;

EID: 84994052029     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep36160     Document Type: Article

References (50)

1. Poynard, T., Yuen, M. F., Ratziu, V. & Lai, C. L. Viral hepatitis C. Lancet 362, 2095-2100 (2003).
2. Bühler, S. & Bartenschlager, R. Promotion of hepatocellular carcinoma by hepatitis C virus. Dig Dis. 30, 445-452 (2012).
3. Park, H. et al. IL-29 is the dominant type III interferon produced by hepatocytes during acute hepatitis C virus infection. Hepatology 56, 2060-2070 (2012).
4. Lauer, G. M. Immune responses to hepatitis C virus (HCV) infection and the prospects for an effective HCV vaccine or immunotherapies. J. Infect Dis. 207 Suppl 1, S7-S12 (2013).
5. Hoofnagle, J. H. Course and outcome of hepatitis C. Hepatology 36, S21-S29 (2002).
6. Quarleri, J. F. & Oubiña, J. R. Hepatitis C virus strategies to evade the specific-T cell response: a possible mission favoring its persistence. Ann Hepatol. 15, 17-26 (2015).
7. Raziorrouh, B. et al. Virus-specific CD4+ T Cells Have Functional and Phenotypic Characteristics of Follicular T-helper Cells in Patients With Acute and Chronic HCV Infections. Gastroenterology 150, 696-706 (2016).
8. Sun, J., Rajsbaum, R. & Yi, M. Immune and non-immune responses to hepatitis C virus infection. World J Gastroenterol. 21, 10739-10748 (2015).
9. Dong, Z., Wei, H., Sun, R. & Tian, Z. The roles of innate immune cells in liver injury and regeneration. Cell Mol Immunol. 4, 241-252 (2007).
10. Revie, D. & Salahuddin, S. Z. Role of macrophages and monocytes in hepatitis C virus infections. World J Gastroenterol. 20, 2777-2784 (2014).
11. Murray, P. J. & Wynn, T. A. Protective and pathogenic functions of macrophage subsets. Nat Rev Immunol. 11, 723-737 (2011).
12. Yao, Z. et al. Role of the exogenous HCV core protein in the interaction of human hepatocyte proliferation and macrophage subpopulations. PLoS One 9, e108278 (2014).
13. Hoppstädter, J. et al. M2 polarization enhances silica nanoparticle uptake by macrophages. Front Pharmacol. 6, 55 (2015).
14. Saha, B. & Szabo, G. Innate immune cell networking in hepatitis C virus infection. J. Leukoc Biol. 96, 757-766 (2014).
15. Fan, C. et al. Up-regulation of A20/ABIN1 contributes to inefficient M1 macrophage polarization during Hepatitis C virus infection. Virol J. 12, 147 (2015).
16. Kunkel, M. & Watowich, S. J. Conformational changes accompanying self-assembly of the hepatitis C virus core protein. Virology 294, 239-245 (2002).
17. Chang, S., Dolganiuc, A. & Szabo, G. Toll-like receptors 1 and 6 are involved in TLR2-mediated macrophage activation by hepatitis C virus core and NS3 proteins. J. Leukoc Biol. 82, 479-487 (2007).
18. Tan, S. L. & Hepatitis C. Viruses: Genomes and Molecular Biology. Norfolk (UK): Horizon Bioscience 2006.
19. Chung, H., Watanabe, T., Kudo, M. & Chiba, T. Hepatitis C virus core protein induces homotolerance and cross-tolerance to Tolllike receptor ligands by activation of Toll-like receptor 2. J. Infect Dis. 202, 853-861 (2010).
20. Berzsenyi, M. D. et al. Hepatic TLR2 & TLR4 expression correlates with hepatic inflammation and TNF-alpha in HCV & HCV/HIV infection. J. Viral Hepat. 18, 852-860 (2011).
21. Tu, Z. et al. HCV core and NS3 proteins manipulate human blood-derived dendritic cell development and promote Th 17 differentiation. Int Immunol. 24, 97-106 (2012).
22. Ohkoshi, S., Hirono, H. & Yamagiwa, S. Direct antiviral agent treatment of decompensated hepatitis C virus-induced liver cirrhosis. World J Gastrointest Pharmacol Ther. 6, 114-119 (2015).
23. Dolganiuc, A. et al. Hepatitis C core and nonstructural 3 proteins trigger toll-like receptor 2-mediated pathways and inflammatory activation. Gastroenterology 127, 1513-1524 (2004).
24. Hu, X., Chen, J., Wang, L. & Ivashkiv, L. B. Crosstalk among Jak-STAT, Toll-like receptor, and ITAM-dependent pathways in macrophage activation. J. Leukoc Biol. 82, 237-243 (2007).
25. Rauch, I., Müller, M. & Decker, T. The regulation of inflammation by interferons and their STATs. Jakstat. 2, e23820 (2013).
26. Biswas, S. K. & Lewis, C. E. NF-κ B as a central regulator of macrophage function in tumors. J. Leukoc Biol. 88, 877-884 (2010).
27. Martinez, F. O., Helming, L. & Gordon, S. Alternative activation of macrophages: an immunologic functional perspective. Annu Rev Immunol. 27, 451-483 (2009).
28. Szabo, G. & Dolganiuc, A. Hepatitis C and innate immunity: recent advances. Clin Liver Dis. 12, 675-692, (2008).
29. Hamilton, J. A. Colony-stimulating factors in inflammation and autoimmunity. Nat Rev Immunol. 8, 533-544 (2008).
30. Biswas, S. K., Chittezhath, M., Shalova, I. N. & Lim, J. Y. Macrophage polarization and plasticity in health and disease. Immunol Res. 53, 11-24 (2012).
31. Gutierrez, J. A., Lawitz, E. J. & Poordad, F. Interferon-free, direct-acting antiviral therapy for chronic hepatitis C. J. Viral Hepat. 22, 861-870 (2015).
32. Ascher, D. B. et al. Potent hepatitis C inhibitors bind directly to NS5A and reduce its affinity for RNA. Sci Rep. 4, 4765 (2014).
33. Lin, J. C. et al. Interferon gamma-induced protein 10 kinetics in treatment-naive versus treatment-experienced patients receiving interferon-free therapy for hepatitis C virus infection: implications for the innate immune response. J. Infect Dis. 210, 1881-1885 (2014).
34. Zhai, N. et al. Hepatitis C virus core protein triggers expansion and activation of CD4(+ )CD25(+ ) regulatory T cells in chronic hepatitis C patients. Cell Mol Immunol. 12, 743-749 (2015).
35. Tu, Z. et al. Hepatitis C virus core protein subverts the antiviral activities of human Kupffer cells. Gastroenterology 138, 305-314 (2010).
36. Galli, S. J., Borregaard, N. & Wynn, T. A. Phenotypic and functional plasticity of cells of innate immunity: macrophages, mast cells and neutrophils. Nat Immunol. 12, 1035-1044 (2011).
37. Melén, K., Fagerlund, R., Nyqvist, M., Keskinen, P. & Julkunen, I. Expression of hepatitis C virus core protein inhibits interferoninduced nuclear import of STATs. J. Med Virol. 73, 536-547 (2004).
38. Xu, W. & Banchereau, J. The antigen presenting cells instruct plasma cell differentiation. Front Immunol. 4, 504 (2014).
39. Landi, A., Yu, H. & Babiuk, L. A. & van, Drunen, Littel-van, den, Hurk, S. Human dendritic cells expressing hepatitis C virus core protein display transcriptional and functional changes consistent with maturation. J. Viral Hepat. 18, 700-713 (2011).
40. Mantovani, A., Germano, G., Marchesi, F., Locatelli, M. & Biswas, S. K. Cancer-promoting tumor-associated macrophages: new vistas and open questions. Eur J Immunol. 41, 2522-2525 (2011).
41. Semmo, N., Krashias, G., Willberg, C. & Klenerman, P. Analysis of the relationship between cytokine secretion and proliferative capacity in hepatitis C virus infection. J. Viral Hepat. 14, 492-502 (2007).
42. Wonderlich, E. R., Wu, W. C., Normolle, D. P. & Barratt-Boyes, S. M. Macrophages and Myeloid Dendritic Cells Lose T Cell-Stimulating Function in Simian Immunodeficiency Virus Infection Associated with Diminished IL-12 and IFN-α Production. J. Immunol. 195, 3284-3292 (2015).
43. Lee, C. H. et al. Hepatitis C virus core protein inhibits interleukin 12 and nitric oxide production from activated macrophages. Virology 279, 271-279 (2001).
44. Petrasek, J. et al. IL-1 receptor antagonist ameliorates inflammasome-dependent alcoholic steatohepatitis in mice. J. Clin Invest. 122, 3476-3489 (2012).
45. You, Q., Cheng, L., Kedl, R. M. & Ju, C. Mechanism of T cell tolerance induction by murine hepatic Kupffer cells. Hepatology 48, 978-990 (2008).
46. Bility, M. T. et al. Hepatitis B virus infection and immunopathogenesis in a humanized mouse model: induction of human-specific liver fibrosis and M2-like macrophages. PLoS Pathog. 10, e1004032 (2014).
47. Jaguin, M., Houlbert, N., Fardel, O. & Lecureur, V. Polarization profiles of human M-CSF-generated macrophages and comparison of M1-markers in classically activated macrophages from GM-CSF and M-CSF origin. Cell Immunol. 281, 51-61 (2013).
48. Graham, D. B. et al. An ITAM-signaling pathway controls cross-presentation of particulate but not soluble antigens in dendritic cells. J. Exp Med. 204, 2889-2897 (2007).
49. Ablin, J., Verbovetski, I., Trahtemberg, U., Metzger, S. & Mevorach, D. Quinidine and procainamide inhibit murine macrophage uptake of apoptotic and necrotic cells: a novel contributing mechanism of drug-induced-lupus. Apoptosis 10, 1009-1018 (2005).
50. Beider, K. et al. Multiple myeloma cells recruit tumor-supportive macrophages through the CXCR4/CXCL12 axis and promote their polarization toward the M2 phenotype. Oncotarget 5, 11283-11296 (2014).